Financial

News

Novartis looking into future of its Sandoz' generics busines...

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.

News

Acceleron investors dig their heels in on Merck takeover bid

Activist investors are pushing back against Merck & Co's recent $11.5 billion deal to acquire Acceleron Pharma, arguing that its $180-per-share offer seriously undervalues the company.

News

Biogen's Aduhelm rollout goes from bad to worse

Analysts were predicting sales of Biogen's recently approved Alzheimer's therapy Aduhelm may start to gather a little momentum in the third quarter, but the drug seems to be going into reve

News

J&J mulls switch from non-profit status for COVID jab

Johnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became available, but is thinking about a possible switch to a standard commercial model

News

Delta variant keeps Roche diagnostics sales sky high

High demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche's diagnostics division, allowing the company to raise its sales forecast for the year.

News

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on

Novartis looking into future of its Sandoz' generics busines...

Acceleron investors dig their heels in on Merck takeover bid

Biogen's Aduhelm rollout goes from bad to worse

J&J mulls switch from non-profit status for COVID jab

Delta variant keeps Roche diagnostics sales sky high

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Financial

Editor's Picks